Yes, targeting SAC components offers a promising avenue for cancer therapy. Inhibitors of MPS1 kinase, for example, are being explored in clinical trials. These inhibitors can enhance the effectiveness of existing treatments like taxanes by exacerbating mitotic defects in cancer cells. Additionally, exploiting SAC weaknesses in cancer cells can selectively induce apoptosis in cancer cells while sparing normal cells.
